

Pharmacoeconomics

When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development?

A Systematic Review of NICE Guidance

Louise Longworth, JiHee Youn, Laura Bojke, Stephen Palmer, Susan Griffin, Eldon Spackman, Karl Claxton

Correspondence

Louise Longworth, Health Economics Research Group, Brunel University, Uxbridge, Middlesex, UB3 3PH, UK
e-mail: louise.longworth@brunel.ac.uk

Electronic Supplementary Material

Supplementary table: Appraisals including OIR or AWR recommendations in draft/final guidance

TA	Title	Date	ACD/ FAD
2	Prostheses for primary total hip replacement	April 2000	FAD only*
5	Cervical cancer - liquid based cytology	May 2000	FAD only*
6	Taxanes for Breast cancer	June 2000	FAD only*
8	Hearing aid technology	July 2000	FAD only*
16	Knee joints (defective) - autologous cartilage transplantation	Dec 2000	FAD only*
17	Colorectal cancer - laparoscopic surgery	Dec 2000	FAD only*
23	Recurrent malignant glioma (Brain cancer) - temozolomide	April 2001	FAD only*
30	Taxanes for Breast cancer	Sept 2001	FAD only*
33	Colorectal cancer (advanced) - irinotecan, oxaliplatin & raltitrexed	March 2002	FAD only*
35	Arthritis (juvenile idiopathic) - etanercept	March 2002	FAD only*
36	Rheumatoid arthritis - Etanercept and infliximab	March 2002	FAD only*
37	Lymphoma (follicular non-Hodgkin's) - rituximab	March 2002	FAD only*
44	Hip disease - metal on metal hip resurfacing	June 2002	ACD & FAD
50	Leukaemia (chronic myeloid) - imatinib	May 2002	ACD only
51	Depression and anxiety - computerised cognitive behaviour therapy (CCBT)	Oct 2002	ACD & FAD
60	Diabetes - patient education models	Nov 2002	ACD only
65	Aggressive Non-Hodgkin's lymphoma - rituximab	Sept 2003	ACD & FAD
68	Macular degeneration (age-related) - photodynamic therapy	Sept 2003	ACD & FAD
70	Leukaemia (chronic myeloid) - imatinib	Oct 2003	FAD only
72	Rheumatoid arthritis - anakinra	Nov 2003	ACD & FAD
75	Hepatitis C - pegylated interferons, ribavirin and alfa interferon	Jan 2004	ACD & FAD
86	Gastro-intestinal stromal tumours (GIST) - imatinib	May 2004	ACD only
89	Cartilage injury - autologous chondrocyte implantation (ACI)	May 2005	ACD & FAD
92	Tooth decay - HealOzone	July 2005	FAD only
93	Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed	Aug 2005	ACD & FAD
97	Depression and anxiety - computerised cognitive behavioural therapy	Feb 2006	ACD & FAD
99	Immunosuppressive therapy for renal transplantation in children and adolescents	April 2006	FAD only
104	Psoriatic arthritis - etanercept and infliximab	June 2005	ACD only
111	Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine	Nov 2006†	ACD & FAD
113	Diabetes (type 1 and 2) - inhaled insulin	Dec 2006	ACD & FAD
121	Glioma - carmustine implants and temozolomide	Dec 2005	ACD only
129	Multiple myeloma - bortezomib	July 2006	ACD only
130	Rheumatoid arthritis - adalimumab, etanercept and infliximab	Feb 2006	ACD only
135	Mesothelioma - pemetrexed disodium	March 2006	ACD only
142	Anaemia - erythropoietin (alpha and beta) and darbepoetin	July 2005	ACD only
143	Ankylosing spondylitis - adalimumab, etanercept and infliximab	July 2007	ACD only
159	Pain (chronic neuropathic or ischaemic) - spinal cord stimulation	Oct 2008	ACD & FAD
163	Ulcerative colitis (acute exacerbations) - infliximab	Dec 2008	ACD & FAD
166	Hearing impairment - cochlear implants	Dec 2007	ACD only
167	Abdominal aortic aneurysm - endovascular stent-grafts	Feb 2009	ACD & FAD

*ACDs were not publicly available for these appraisals. †Updated in 2009. FAD refers to final guidance.